Related Experiment Videos
Role of newer medications for bipolar disorder
1Department of Psychiatry, University of Texas Health Science Center, San Antonio, USA.
Abstract:
The quest for additional effective therapies for bipolar study commenced in the 1960s, even before regulatory approval of lithium. This was driven by the recognition that patient response to lithium varied from excellent to poor; thus, significant numbers of patients faced its frequent adverse effects and risks without sustaining any benefit. These needed advances have been slowed by the unusual difficulties of studying bipolar disorder in controlled, rigorously designed protocols. These difficulties are reviewed both from the perspective of their effects on research and on clinical practice. In addition, the results of two blinded, placebo-controlled studies of divalproex in the treatment of acute mania are compared with results from earlier open and comparator studies. The comparisons indicate that open-study results with divalproex and other forms of valproic acid have yielded results quite similar to those observed under rigorous study conditions. Whereas substantial evidence exists regarding the efficacy of divalproex and carbamazepine and their roles in treating patients with bipolar disorder, studies evaluating other putative mood-stabilizing agents and antidepressants in bipolar disorder are few in number and inconsistent in results. With few exceptions, studies of these latter drugs do not provide clear guidelines for treatment.
Insights
Research for new bipolar disorder treatments began in the 1960s due to varied lithium responses. Divalproex shows consistent efficacy in acute mania, unlike other agents with limited evidence.
Area of Science:
- Psychiatry and Pharmacology
- Neuroscience of Mood Disorders
Background:
- Lithium, a primary treatment for bipolar disorder since the 1960s, exhibits variable patient response and significant adverse effects.
- Challenges in designing rigorous controlled studies for bipolar disorder have historically impeded the development of novel therapies.
Purpose of the Study:
- To review the difficulties in studying bipolar disorder and compare efficacy data for divalproex in acute mania.
- To assess the current evidence base for mood-stabilizing agents and antidepressants in bipolar disorder treatment.
Main Methods:
- Comparison of results from two blinded, placebo-controlled studies of divalproex with earlier open and comparator studies.
- Review of research challenges impacting clinical practice and study design in bipolar disorder.
Main Results:
- Open-study results for divalproex (a form of valproic acid) align with findings from rigorous controlled trials, confirming its efficacy in acute mania.
- Substantial evidence supports the efficacy of divalproex and carbamazepine for bipolar disorder.
- Limited and inconsistent results exist for other mood stabilizers and antidepressants, offering few clear treatment guidelines.
Conclusions:
- Divalproex is a well-established treatment for acute mania in bipolar disorder, supported by consistent evidence.
- The development of effective treatments for bipolar disorder remains challenging due to research complexities.
- Further research is needed for other mood-stabilizing agents and antidepressants to establish clear treatment guidelines.